588 related articles for article (PubMed ID: 11173657)
21. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma.
Yang Q; Sakurai T; Jing X; Utsunomiya H; Shan L; Nakamura Y; Nakamura M; Oura S; Suzuma T; Yoshimura G; Umemura T; Kokawa Y; Kakudo K
Pathol Int; 1999 Sep; 49(9):775-80. PubMed ID: 10504548
[TBL] [Abstract][Full Text] [Related]
22. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
[TBL] [Abstract][Full Text] [Related]
23. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
24. Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast.
Tan PH; Chuah KL; Chiang G; Wong CY; Dong F; Bay BH
Oncol Rep; 2002; 9(5):1081-6. PubMed ID: 12168077
[TBL] [Abstract][Full Text] [Related]
25. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
[TBL] [Abstract][Full Text] [Related]
26. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
27. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
28. [Histological grading in ductal carcinoma in situ of the breast].
Xu W; Zhu X; Zhang T; Tu X; Shi D
Zhonghua Bing Li Xue Za Zhi; 1999 Oct; 28(5):331-3. PubMed ID: 11869542
[TBL] [Abstract][Full Text] [Related]
29. Histological grade (HG) in invasive ductal carcinomas of the breast of less than 1 cm: clinical and biological associations during progression from HG1 to HG3.
Ruibal Á; Aguiar P; Del Rio MC; Arias JI; Menéndez-Rodríguez P; Gude F; Herranz M
Anticancer Res; 2015 Jan; 35(1):569-73. PubMed ID: 25550604
[TBL] [Abstract][Full Text] [Related]
30. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
31. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
32. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
Wan D; Zhang Y; Yu Q; Li F; Zhuo J
Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
[TBL] [Abstract][Full Text] [Related]
33. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
[TBL] [Abstract][Full Text] [Related]
34. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
35. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
[TBL] [Abstract][Full Text] [Related]
36. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
Bos R; Zhong H; Hanrahan CF; Mommers EC; Semenza GL; Pinedo HM; Abeloff MD; Simons JW; van Diest PJ; van der Wall E
J Natl Cancer Inst; 2001 Feb; 93(4):309-14. PubMed ID: 11181778
[TBL] [Abstract][Full Text] [Related]
37. Is there 'progression through grade' in ductal invasive breast cancer?
Schymik B; Buerger H; Krämer A; Voss U; van der Groep P; Meinerz W; van Diest PJ; Korsching E
Breast Cancer Res Treat; 2012 Oct; 135(3):693-703. PubMed ID: 22886478
[TBL] [Abstract][Full Text] [Related]
38. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma.
Karray-Chouayekh S; Baccouche S; Khabir A; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
Acta Histochem; 2011 Sep; 113(5):508-13. PubMed ID: 20598349
[TBL] [Abstract][Full Text] [Related]
40. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
